BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Status: Closed to Accrual
Learn more:
- clinicaltrials.gov: #NCT03285321
- See Study Locations on Big Ten CRC Website
Study Contact: studies@hoosiercancer.org; (317) 921-2050.
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter